GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Gross-Profit-to-Asset %

Acticor Biotech (XPAR:ALACT) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Acticor Biotech's annualized Gross Profit for the quarter that ended in Jun. 2023 was €0.00 Mil. Acticor Biotech's average Total Assets over the quarter that ended in Jun. 2023 was €13.62 Mil. Therefore, Acticor Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 0.00%.


Acticor Biotech Gross-Profit-to-Asset % Historical Data

The historical data trend for Acticor Biotech's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Gross-Profit-to-Asset % Chart

Acticor Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 0.74 - - - -

Acticor Biotech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Acticor Biotech's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Acticor Biotech's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acticor Biotech's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acticor Biotech's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Acticor Biotech's Gross-Profit-to-Asset % falls into.



Acticor Biotech Gross-Profit-to-Asset % Calculation

Acticor Biotech's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (17.881+12.943)/ 2 )
=0/15.412
=0.00 %

Acticor Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=0/( (12.943+14.302)/ 2 )
=0/13.6225
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Acticor Biotech Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acticor Biotech (XPAR:ALACT) Business Description

Traded in Other Exchanges
Address
82 Avenue du Maine, Wojo Building, Paris, FRA, 75014
Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines